

Chapter 249

Superiority by a Margin Tests for Vaccine Efficacy using the Ratio of Two Poisson Rates in a Cluster-Randomized Design

Introduction

This procedure calculates power and sample size for superiority by a margin tests of vaccine efficacy (VE) using the ratio of two rates in a cluster-randomized design in which the outcome variable is a count. It uses the work of Wang, Zhang, and Ahn (2018) which give the power for the case of varying cluster sizes. The analysis uses a simple z-test comparing the two rates.

VE is a traditional index of the protective efficacy of a vaccine. It is calculated as

$$VE = \frac{\lambda_2 - \lambda_1}{\lambda_2} = 1 - \frac{\lambda_1}{\lambda_2}$$

where λ_1 and λ_2 are *incidence rates* of the disease being studied among those vaccinated with a certain vaccine and those not vaccinated with that vaccine. An incidence rate is the average number of events per subject per unit of time. An analysis of vaccine effectiveness reduces to an analysis of the ratio of two incidence rates.

Note that because $\lambda_2 > \lambda_1$, the value of $VE < 1$.

Cluster-randomized designs are those in which whole clusters of subjects (classes, hospitals, communities, etc.) are put into the treatment group or the control group. Generally speaking, the larger the cluster sizes and the higher the correlation among subjects within the same cluster, the larger will be the overall sample size necessary to detect an effect with the same power.

Hypotheses

When higher rates are worse such as in this procedure, the superiority by a margin test hypotheses are

$$H_0: VE \leq VE_0 \quad \text{vs.} \quad H_1: VE > VE_0$$

Superiority by a Margin Tests for Vaccine Efficacy using the Ratio of Two Poisson Rates in a Cluster-Randomized Design

Technical Details

The following discussion summarizes the results in Wang, Zhang, and Ahn (2018).

Suppose you are interested in comparing the incidence rates of two groups (treatment and control) with a superiority by a margin test. Further suppose that the response is known to be related to other covariates (such as age, race, or gender) and so their impact needs to be adjusted for. This may be accomplished by stratifying on the covariates and forming hypotheses about a common mean difference across all clusters and strata. Often, the stratification is based on cluster size, but this is not required.

Let Y_{jki} be the count outcome of the i th ($i = 1, \dots, M_{jk}$) subject in the k th ($k = 1, \dots, K_j$) cluster of the j th ($j = 1, 2$) group. Assuming that Y_{jki} follows a Poisson model with

$$\lambda_j = E(Y_{jki}) = \text{Var}(Y_{jki})$$

and a common intracluster correlation coefficient (ICC) $\rho = \text{corr}(Y_{jki}, Y_{jki'})$ for $i \neq i'$.

Test Statistic

An unbiased estimator of λ_j is

$$\hat{\lambda}_j = \frac{\sum_{k=1}^{K_j} \sum_{i=1}^{M_{jk}} Y_{jki}}{\sum_{k=1}^{K_j} M_{jk}}$$

with estimated variance

$$s_j^2 = \frac{\hat{\lambda}_j \sum_{k=1}^{K_j} M_{jk} [1 + (M_{jk} - 1)\hat{\rho}]}{\left(\sum_{k=1}^{K_j} M_{jk}\right)^2}$$

Using a one-sided hypothesis $H_0: \lambda_1 = \lambda_2$ versus $H_1: \lambda_1 < \lambda_2$, H_0 is rejected if

$$\frac{\hat{\lambda}_1 - \hat{\lambda}_2}{\sqrt{s_1^2 + s_2^2}} > z_{1-\alpha}$$

Sample Size and Power

Wang, Zhang, and Ahn (2018) provide the following formula for estimating K_2 (the number of clusters in the control group) when there are an unequal number of clusters in each group.

$$K_2 = \frac{\left(z_{1-\frac{\alpha}{2}} + z_{1-\beta}\right)^2 \left(\frac{\lambda_1}{R} + \lambda_2\right)}{(\lambda_1 - \lambda_2)^2} \left[(1 - \rho) \frac{1}{\theta} + \rho + \rho\gamma^2 \right]$$

where $R = K_1/K_2$, $M = E(M_{jk})$, $\tau^2 = \text{Var}(M_{jk})$, and $\gamma = \tau/M$. Here M is the average cluster size of all clusters in the study and γ is the coefficient of variation of the cluster sizes. Note that $z_x = \Phi(x)$ is the standard normal distribution function.

This equation can easily be rearranged to provide a formula for power $(1 - \beta)$.

Superiority by a Margin Tests for Vaccine Efficacy using the Ratio of Two Poisson Rates in a Cluster-Randomized Design

Example 1 – Finding the Number of Clusters

A vaccine efficacy study is being planned to investigate whether a new intervention will decrease the incidence rate of a certain disease over the rate achieved by the current intervention. The response is a count. For a number of reasons, the researchers decide to administer the intervention to whole clusters (clinics) rather than randomize the treatment to individuals within a cluster. The number of clinics receiving each treatment will be balanced.

The average number of subjects per clinic is 21. The coefficient of variation of the cluster sizes is 0.42.

Prior studies have obtained an incidence rate of 0.35 for the current treatment and an ICC of 0.02. The vaccine efficacy superiority bound is set to 0.6. The researchers want to compare the necessary sample size when the actual efficacy is 0.7 0.8 0.9.

The one-sided significance level is set to 0.025 and the power is set to 0.8.

Setup

This section presents the values of each of the parameters needed to run this example. First, from the PASS Home window, load this procedure. You may then make the appropriate entries as listed below, or open **Example 1** by going to the **File** menu and choosing **Open Example Template**.

Option	Value
Design Tab	
Solve For	K1 (Number of Clusters in Group 1)
Power.....	0.80
Alpha.....	0.025
K2 (Clusters in Group 2).....	K1
M (Average of Cluster Sizes).....	21
CV (Coef of Variation of Cluster Sizes)	0.42
Vaccine Efficacy Input Type	Vaccine Efficacies (VE0 and VE1)
VE0 (Superiority Vaccine Efficacy).....	0.65
VE1 (Actual Vaccine Efficacy)	0.7 0.8 0.9
λ_2 (Incidence Rate of Control Group).....	0.04
ρ (Intracluster Correlation, ICC).....	0.02

Annotated Output

Click the Calculate button to perform the calculations and generate the following output.

Numeric Results

Numeric Results													
Hypothesis: $H_0: VE \leq VE_0$ vs. $H_1: VE > VE_0$													
Power	Sample Size	Clusters		Cluster Size		Incidence Rates			Vaccine Efficacy			Alpha	
		Grp 1	Grp 2	Ave	COV	Sup	Act	Cntl	Sup	Act	ICC		
	N	K1	K2	M	CV	$\lambda_{1.0}$	$\lambda_{1.1}$	λ_2	VE0	VE1	ρ		
0.81451	924	22	22	21	0.42	0.014	0.012	0.04	0.65	0.7	0.02	0.025	
0.80152	756	18	18	21	0.42	0.014	0.008	0.04	0.65	0.8	0.02	0.025	
0.80865	630	15	15	21	0.42	0.014	0.004	0.04	0.65	0.9	0.02	0.025	

Superiority by a Margin Tests for Vaccine Efficacy using the Ratio of Two Poisson Rates in a Cluster-Randomized Design

References

- Blackwelder, William C. 1993. 'Sample Size and Power for Prospective Analysis of Relative Risk.' *Statistics in Medicine*, Vol. 12, 691-698.
- Nauta, Jozef. 2020. *Statistics in Clinical and Observational Vaccine Studies*, 2nd Edition. Springer. Cham, Switzerland.
- Wang, J., Zhang, S., and Ahn, C. 2018. 'Sample size calculation for count outcomes in cluster randomization trials with varying cluster sizes.' *Communications in Statistics--Theory and Methods*, DOI: 10.1080/03610926.2018.1532004.

Report Definitions

$$VE = 1 - \lambda_1 / \lambda_2.$$

Power is the probability of rejecting a false null hypothesis. It should be close to one.

N is the total sample size, i.e., the total number of subjects from all clusters.

K1 is the number of clusters assigned to group 1, the treatment group.

K2 is the number of clusters assigned to group 2, the control group.

M is the average cluster size. It is the anticipated average number of subjects per cluster.

CV is the coefficient of variation of the cluster sizes. It is the standard deviation of cluster sizes divided by the average cluster size.

$\lambda_{1.0}$ is the superiority bound on incidence rate in the treatment group.

$\lambda_{1.1}$ is the actual incidence rate of the treatment group at which the power is computed.

λ_2 is the incidence rate in the control group.

VE0 is the vaccine efficacy assumed by the null hypothesis. This is the superiority boundary. $VE0 = 1 - \lambda_{1.0} / \lambda_2$.

VE1 is the vaccine efficacy assumed by the alternative hypothesis. This is the VE at which the power is computed. $VE1 = 1 - \lambda_{1.1} / \lambda_2$.

ρ is the intraclass correlation coefficient. This is the correlation between any two subjects within a particular cluster.


Alpha is the probability of rejecting a true null hypothesis.

Summary Statements

A cluster-randomized, superiority by a margin design consists of 22 treatment clusters and 22 control clusters. Each cluster is assumed to have an average of 21 subjects per cluster. The outcome of the study will be analyzed by comparing the vaccine efficacies of a treatment and a control group to a superiority boundary. Higher values of these incidence rates are assumed to be worse. The expected sample size of 924 subjects achieves 81% power to reject non-superiority when the actual vaccine efficacy is 0.7. The superiority bound of vaccine efficacy is 0.65. The incidence rate of the control group 0.04. The incidence rate of the treatment group assumed by the alternative hypothesis is 0.012. The incidence rate of the treatment group which is the superiority bound is 0.014. The intraclass correlation coefficient is 0.02. The significance level of the test is 0.025. The individual cluster sizes (the number of subjects per cluster) are assumed to vary according to a discrete distribution with mean 21 and coefficient of variation 0.42.

Chart Section

Chart Section



The values from the Numeric Results report are displayed in this plot.

Superiority by a Margin Tests for Vaccine Efficacy using the Ratio of Two Poisson Rates in a Cluster-Randomized Design

Example 2 – Validation using a Previously Validated Procedure

We could not find a validation example in the literature so we will use a previously validated procedure in **PASS** to validate this procedure. That procedure is “Superiority by a Margin Tests for the Ratio of Two Poisson Rates in a Cluster-Randomized Design” with the following settings. Set Higher Rates Are to “Worse”, power = 0.9, alpha = 0.025, K2 = K1, M = 20, CV = 0.4, $\lambda_{1.0} = 0.5$, $\lambda_{1.1} = 0.4$, $\lambda_2 = 0.6$, and $\rho = 0.02$. The solution is K1 = K2 = 69.

To run this example in the current procedure, set power = 0.9, alpha = 0.025, K2 = K1, M = 20, CV = 0.4, $\lambda_{1.0} = 0.5$, $\lambda_{1.1} = 0.4$, $\lambda_2 = 0.6$, and $\rho = 0.02$. Solve for K1.

Setup

This section presents the values of each of the parameters needed to run this example. First, from the **PASS** Home window, load this procedure. You may then make the appropriate entries as listed below, or open **Example 2** by going to the **File** menu and choosing **Open Example Template**.

Option	Value
Design Tab	
Solve For	K1 (Number of Clusters in Group 1)
Power.....	0.9
Alpha.....	0.025
K2 (Clusters in Group 2)	K1
M (Average of Cluster Sizes).....	20
CV (Coef of Variation of Cluster Sizes)	0.4
Vaccine Efficacy Input Type	Incidence Rates ($\lambda_{1.0}$ and $\lambda_{1.1}$)
$\lambda_{1.0}$ (Superiority Incidence Rate)	0.5
$\lambda_{1.1}$ (Actual Incidence Rate)	0.4
λ_2 (Incidence Rate of Control Group).....	0.6
ρ (Intracluster Correlation, ICC).....	0.02

Output

Click the Calculate button to perform the calculations and generate the following output.

Numeric Results

Numeric Results													
Hypothesis: H0: VE ≤ VE0 vs. H1: VE > VE0													
Power	Sample Size N	Clusters		Cluster Size		Incidence Rates			Vaccine Efficacy			ICC ρ	Alpha
		Grp 1 K1	Grp 2 K2	Ave M	COV CV	Sup $\lambda_{1.0}$	Act $\lambda_{1.1}$	Cntl λ_2	Sup VE0	Act VE1			
0.90297	2760	69	69	20	0.4	0.5	0.4	0.6	0.16667	0.33333	0.02	0.025	

PASS has also obtained K1 = K2 = 69. Thus, the procedure is validated.